is tirzepatide still in shortage news FDA confirms over, gives compounders a grace period Tirzepatide is NO longer – Mounjaro and Zepbound Are No – FDA says this weight loss

The evidence is weak

Month 2: More Consistent Fat Loss By month two, many patients reach a dose where effects are more noticeable: More consistent weekly weight loss Reduced snacking Improved eating control Better energy for some patients Typical cumulative loss by 2 months: 614 pounds Month 3: Visible Before and After Changes By month three, changes are often more noticeable: Clothing fitting looser Waist circumference reduction Improved metabolic labs Increased motivation Typical cumulative loss by 3 months: 818+ pounds 510% of starting body weight 6-Month and 12-Month Results From a medical perspective, semaglutide shows its greatest value over time

The Medicare GLP-1 Bridge (live since July 1, 2026) covers all Wegovy formulations for weight loss at $50/month for eligible Part D beneficiariesno CV diagnosis required, just the BMI-based eligibility criteria and prescriber prior authorization

In this group, 963 participants using GLP-1RAs developed depression, and 1,075 participants using DPP4is developed depression

Where Is Tirzepatide Used